Galderma Receives U.S. FDA Approval for Differin庐 Epiduo庐 Acne Gel Prescription-to-OTC Switch

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older
Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin庐 and Epiduo庐 heritage
Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter
The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care.

This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription

上一篇：《直播时刻效应》：Genius Sports与MediaScience的研究显示直播体育比赛的特定时刻可能会使无辅助品牌回忆翻倍

下一篇：Omdia：到2030年，Amazon、Netflix和Google将占据810亿美元联网电视广告市场的半壁江山

推荐资讯

中国浓香白酒核心产区	电影《钢铁意志》今日
长安马自达好不好恩施	年轻人的座驾创酷RS恩

栏目更新

栏目热门